کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5524030 | 1401404 | 2017 | 7 صفحه PDF | دانلود رایگان |
- Adaptive resistance of cancer is often acquired and inherited by genetic changes.
- Current targeted therapies lack clinical steps aimed to preclude genetic changes.
- Depletion of WRN/RecQ helicases triggers replication stress and cell death.
- For future targeted therapies, WRN/RecQ depletion may diminish adaptive resistance.
WRN helicase has several roles in genome maintenance, such as replication, base excision repair, recombination, DNA damage response and transcription. These processes are often found upregulated in human cancers, many of which display increased levels of WRN. Therefore, directed inhibition of this RecQ helicase could be beneficial to selective cancer therapy. Inhibition of WRN is feasible by the use of small-molecule inhibitors or application of RNA interference and EGS/RNase P targeting systems. Remarkably, helicase depletion leads to a severe reduction in cell viability due to mitotic catastrophe, which is triggered by replication stress induced by DNA repair failure and fork progression arrest. Moreover, we present new evidence that WRN depletion results in early changes of RNA polymerase III and RNase P activities, thereby implicating chromatin-associated tRNA enzymes in WRN-related stress response. Combined with the recently discovered roles of RecQ helicases in cancer, current data support the targeting prospect of these genome guardians, as a means of developing clinical phases aimed at diminishing adaptive resistance to present targeted therapies.
Journal: Biochimica et Biophysica Acta (BBA) - Reviews on Cancer - Volume 1867, Issue 1, January 2017, Pages 42-48